Colestipol tablets in adolescents with familial hypercholesterolaemia.
The objective of this study was to examine palatability and side effects of the new tablet formulation of colestipol. A clinical series of 23 boys and 4 girls aged 10-16 years with heterozygous familial hypercholesterolaemia were given 2-12 g colestipol daily for 6 months in an open study. There were no serious side effects. The median reduction in low density lipoprotein cholesterol level was 20%. All preferred the tablets to resin granules they had tried previously. We conclude that low-dose colestipol tablets appear to be safe and effective, and are preferred by adolescents.
Tonstad
S
S
Lipid Clinic, Medical Department A, Rikshospitalet, Oslo, Norway.
Ose
L
L
D000293:Adolescent; D002648:Child; D003084:Colestipol / Q000008:administration & dosage* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D008055:Lipids / Q000097:blood; D008297:Male; D010349:Patient Compliance; D013607:Tablets
D000960:Hypolipidemic Agents; D008055:Lipids; D013607:Tablets; D003084:Colestipol